NervGen Pharma (TSE:NGEN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
NervGen Pharma, a clinical-stage biotech firm, is set to present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The company is known for its innovative approaches to treating nervous system damage and is currently evaluating its lead drug candidate, NVG-291, in clinical trials for spinal cord injury.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
